Semprus BioSciences to develop surface-modified endotracheal tube

Published on November 9, 2012 at 5:16 AM · No Comments

Patients who require respiratory support are typically connected to a ventilator with an endotracheal tube that is inserted in the throat. In intensive care units (ICUs), where patients are ventilated for extended periods of time, bacterial adherence to the endotracheal tube is considered the first step in developing a lung infection, or ventilator-associated pneumonia (VAP).

Although VAP is common in civilian hospital ICUs - with rates as high as 16 cases per 1,000 ventilator days - it is a larger problem in combat military hospitals ICUs with 9.7 to 60.6 cases per 1,000 ventilator days. Late-onset VAP is associated with a mortality rate of up to 65% and more than $60,000 in increased cost per patient.

"Bacterial attachment and proliferation on endotracheal tubes is a contributing factor in the occurrence of VAP in ICU patients," said David L. Lucchino, co-founder and Vice President of Semprus BioSciences. "Through the combined materials approach of the Semprus Sustain Technology and antimicrobial drug release, we expect to reduce bacterial colonization and biofilm formation on the surface of endotracheal tubes which should affect the incidence of VAP."

Source: Teleflex Incorporated

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment